Plasma and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs
- 19 March 2007
- journal article
- clinical trial
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 307-321
- https://doi.org/10.1002/em.20298
Abstract
Several systemic and cellular markers of 3′‐azido‐3′‐dideoxythymidine (AZT) metabolism and AZT incorporation into nuclear DNA were measured in cord blood from uninfected infants born to HIV‐1‐infected mothers receiving prepartum therapies based on AZT or AZT in combination with 2′,3′‐dideoxy‐3′‐thiacytidine (3TC). In addition, the relationships among these pharmacological end points, levels of AZT‐DNA incorporation, and the previously reported mutagenic responses in these infants were evaluated. AZT‐ and 3TC‐specific radioimmunoassays (RIAs), or HPLC coupled with AZT‐RIA, were used to measure plasma levels of AZT and the AZT‐glucuronide, and cellular levels of AZT, phosphorylated AZT, and DNA incorporation of AZT or 3TC in cord blood mononuclear cells from treated infants compared with unexposed controls born to HIV‐uninfected mothers. Fewer infants had detectable AZT‐DNA incorporation levels in the group exposed to AZT (71%; n = 7) compared with those receiving AZT‐3TC (100%; n = 21), and the mean AZT‐DNA incorporation for AZT‐exposed infants (14.6 ± 6.3 AZT/106 nucleotides) was significantly lower than that in AZT‐3TC exposed infants (51.6 ± 10.2 AZT/106 nucleotides; P = 0.028). Low levels of 3TC‐DNA incorporation found in a few AZT‐3TC‐exposed newborns correlated with AZT‐DNA incorporation values in the same samples. Among the metabolites studied, there were positive correlations between levels of AZT‐diphosphate and AZT‐triphosphate, and AZT‐triphosphate and AZT‐DNA incorporation, in nucleoside analog‐exposed infants. Levels of AZT‐DNA incorporation, however, did not correlate well with the reported frequencies of somatic mutations in the same population of nucleoside analog‐treated children. While these data support the continued use of AZT‐based therapies during pregnancy, infants receiving prepartum AZT should be monitored long‐term for adverse health effects. Environ. Mol. Mutagen., 2007.Keywords
This publication has 55 references indexed in Scilit:
- Transplacental carcinogenicity of 3′‐azido‐3′‐deoxythymidine in B6C3F1 mice and F344 ratsEnvironmental and Molecular Mutagenesis, 2007
- Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother–child pairs to AZT or AZT‐3TCEnvironmental and Molecular Mutagenesis, 2007
- Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD‐1 mice to single agents or drug combinationsEnvironmental and Molecular Mutagenesis, 2007
- Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugsToxicology and Applied Pharmacology, 2004
- ZidovudinePediatric Drugs, 2002
- Incorporation of 3´-Azido-3´-Deoxythymidine (AZT) Into Fetal DNA and Fetal Tissue Distribution of Drug After Infusion of Pregnant Late-Term Rhesus Macaques With a Human-Equivalent AZT DoseJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Clinical Pharmacokinetics of ZidovudineClinical Pharmacokinetics, 1996
- Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay methodJournal of Pharmaceutical and Biomedical Analysis, 1996
- Determination of hprt mutant frequencies in T-lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and ageMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
- Intracellular Metabolism of 3′-Azidothymidine in Isolated Human Peripheral Blood Mononuclear CellsAIDS Research and Human Retroviruses, 1991